 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
BASIC SCIENCE |
*Center of Blood Purification Therapy and First Department of Pathology, Wakayama Medical University, Wakayama, Japan; Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan; Division of Nephrology and Dialysis Center, Kobe University School of Medicine, Kobe, Japan; and ||Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan
Correspondence to Dr. Masahide Mizobuchi, 811-1, Kimiidera, Wakayama City, Japan Phone: 81-73-441-0639; Fax: 81-73-441-0639; E-mail: mizobu{at}wakayama-med.ac.jp
The reduced expression level of the calcium-sensing receptor (CaR) is attributed to the hyposensitivity of parathyroid cells to extracellular calcium concentration [Ca2+]o, which plays a crucial role in the pathogenesis of secondary hyperparathyroidism (SHPT) in patients and rats with chronic renal insufficiency (CRI). Calcimimetic compounds have been demonstrated to improve the decreased sensitivity of CaR to extracellular calcium concentration and to suppress both parathyroid hormone (PTH) oversecretion and parathyroid cell proliferation. However, the effect of calcimimetics on the reduced CaR expression level in parathyroid cells in CRI remains unclarified. The aim of this investigation was to examine the effect of the calcimimetic compound NSP R-568 (R-568) on the CaR expression in the parathyroid cells of rats with experimental CRI. Subtotally nephrectomized rats were fed a high-phosphorus diet for 8 (n = 12; Nx-8 group) or 9 wk (n = 11; Nx-9 group) to induce severe SHPT. Another group of uremic rats were fed a high-phosphorus diet for 8 wk and then orally administered R-568 (100 µmol/kg body wt) once a day for 7 d (n = 11; Nx+R-568 group). Sham-operated rats that were fed a standard diet for 9 wk were used as controls (n = 8). R-568 treatment induced a significant reduction in plasma PTH level with significant decrease in serum calcium and without change in serum phosphorus concentration. Serum 1,25(OH)2D3 level was not affected by R-568 administration. CaR mRNA and protein levels in the Nx-8 and Nx-9 groups significantly decreased compared with those in the controls; however, no significant difference in these parameters was observed between the Nx-8 and Nx-9 groups. In the Nx+R-568 group, CaR mRNA and protein levels significantly increased compared with those in either the Nx-8 or Nx-9 group. R-568 was effective in reducing the number of proliferating cell nuclear antigen–positive cells along with parathyroid gland growth suppression in the Nx+R-568 group compared with that in the Nx-9 group. The results suggest that the calcimimetic compound R-568 upregulates decreased CaR expression, and the upregulation possibly has an enhancement effect on PTH secretion and parathyroid cell hyperplasia through the improved sensitivity of CaR to [Ca2+]o.
This article has been cited by other articles:
 |
|
 |
|
  M.-u. Alam, J. P. Kirton, F. L. Wilkinson, E. Towers, S. Sinha, M. Rouhi, T. N. Vizard, A. P. Sage, D. Martin, D. T. Ward, et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells Cardiovasc Res, November 6, 2008; (2008) cvn279v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Komaba, M. Tanaka, and M. Fukagawa Reply Nephrol. Dial. Transplant., November 5, 2008; (2008) gfn587v1. [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Nemeth Anabolic Therapy for Osteoporosis: Calcilytics IBMS BoneKEy, June 1, 2008; 5(6): 196 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Piecha, G. Kokeny, K. Nakagawa, N. Koleganova, A. Geldyyev, I. Berger, E. Ritz, C. P. Schmitt, and M.-L. Gross Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats Am J Physiol Renal Physiol, April 1, 2008; 294(4): F748 - F757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Drueke, D. Martin, and M. Rodriguez Reply Nephrol. Dial. Transplant., January 1, 2008; 23(1): 408 - 409. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Riccardi and D. Martin The Role of the Calcium-Sensing Receptor in the Pathophysiology of Secondary Hyperparathyroidism NDT Plus, January 1, 2008; 1(suppl_1): i7 - i11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Frazao and M. Rodriguez Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy NDT Plus, January 1, 2008; 1(suppl_1): i12 - i17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Drueke, D. Martin, and M. Rodriguez Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1828 - 1839. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Huang and G. E. Breitwieser Rescue of Calcium-sensing Receptor Mutants by Allosteric Modulators Reveals a Conformational Checkpoint in Receptor Biogenesis J. Biol. Chem., March 30, 2007; 282(13): 9517 - 9525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Martin and E. A. Gonzalez Metabolic Bone Disease in Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2007; 18(3): 875 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Reichel Reply Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2989 - 2990. [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
